Ezrin/radixin/moesin (ERM) family members provide a regulated link between the cortical actin cytoskeleton and the plasma membrane to govern membrane structure and organization. Here, we report the crystal structure of intact insect moesin, revealing that its essential yet previously uncharacterized α-helical domain forms extensive interactions with conserved surfaces of the band four-point-one/ezrin/radixin/moesin (FERM) domain. These interdomain contacts provide a functional explanation for how PIP 2 binding and tyrosine phosphorylation of ezrin lead to activation, and provide an understanding of previously enigmatic loss-offunction missense mutations in the tumor suppressor merlin. Sequence conservation and biochemical results indicate that this structure represents a complete model for the closed state of all ERM-merlin proteins, wherein the central α-helical domain is an active participant in an extensive set of inhibitory interactions that can be unmasked, in a rheostat-like manner, by coincident regulatory factors that help determine cell polarity and membrane structure.
Introduction
The plasma membrane is organized into functional regions, with the distinct apical and basolateral domains of polarized epithelial cells providing a well-studied example. To assemble, maintain and regulate the composition and structure of these domains, eukaryotes have evolved proteins that link the underlying cytoskeleton to specific membrane proteins. Among the best understood class are the ezrin/radixin/moesin (ERM) family, which provide a conformationally regulated linkage from the cortical actin cytoskeleton to the plasma membrane, especially in structures like microvilli. 1, 2 ERM proteins consist of three principal domains (Figure 1(a) ). The best characterized of these are the band four-point-one/ezrin/radixin/moesin (FERM) domain 3 and the C-terminal tail domain. The N-terminal ∼300 residue FERM domain consists of three lobes, designated F1, F2 and F3, that are tightly associated in a cloverleaf-like structure. 4 The FERM domain of ERM proteins binds directly to integral membrane proteins, such as CD43, CD44 and ICAM1-3, through their positively charged juxtamembrane regions, [5] [6] [7] [8] [9] or indirectly through Abbreviations used: ERM, ezrin/radixin/moesin; FERM, band four-point-oneERM; Sfmoesin, moesin from Spodoptera frugiperda.
E-mail address of the corresponding author: johntesmer@umich.edu the PDZ-containing scaffolding proteins EBP50/ NHERF and E3KARP. [10] [11] [12] The C-terminal tail domain (often referred to as the C-terminal tail or C-terminal ERM association domain or C-ERMAD) spans the last ∼100 residues and contains an F-actin binding site in the last 30 residues. [13] [14] [15] This domain interacts with the FERM domain as an extended, meandering polypeptide beginning with a β-strand associated with β5 in F3 followed by four helices, the first two of which bind lobe F2 and second two of which bind lobe F3 (Figure 2(a) ). 4 The FERM-tail complex represents a dormant form of the protein in which membrane protein and active binding sites are masked.
Linking the FERM and C-terminal domains is an essential but structurally uncharacterized domain of ∼190 residues, referred to as the α-helical domain, the most conserved feature of which being a heptad repeat characteristic of α-helical coiledcoils ( Figure 1(b) ). 16 This region has been proposed to form an extended helical tether in activated ERM proteins linking the membrane-binding determinants of the FERM domain to the actin-binding determinant at the C-terminal tail. 17 Although crystal structures have been reported for activated FERM domains as well as for the inactive FERM domain complexed with the C-terminal tail domain of human moesin, they have revealed at most only a small portion of the important and enigmatic α-helical domain.
Equally enigmatic is the neurofibromatosis 2 (NF2) tumor suppressor protein merlin, which is closely related to ERM proteins and shares all of the above features except for actin binding. 18, 19 Mutations in merlin that lead to loss of tumor suppression are often disruptive, either truncating the protein or interfering with the proper fold of the protein. Some missense mutations of merlin associated with NF2 have been mapped to the interface of the FERM and C-terminal tail domain, 4 suggesting that their association is critical for tumor suppressor activity. However, many more mutations remain unexplained, given the currently available models.
A particularly interesting aspect of ERM proteins is that they can exist in at least two conformational states, 1 an active open form with the FERM and C-terminal tail domain dissociated, and a dormant closed form similar to that described for the human moesin FERM-C-terminal tail domain complex. 4 Dissociation of the FERM and C-terminal tail domains unmasks binding sites for other proteins. EBP50 binds to a region of the FERM domain that overlaps with the C-terminal tail, 20, 21 and the ICAM-2 receptor binds to the radixin FERM domain at a site analogous to the first β-strand in the Cterminal tail. 22 This site is analogous to where integrin tails anchor to the talin FERM domain, 23 and to where a regulatory intramolecular linker region interacts with the FERM domain of focal adhesion kinase. 24 Evidence suggests these states are regulated primarily by the phosphorylation of a threonine residue in the C-terminal domain (equivalent to Thr558 in moesin) and/or the binding of PIP 2 .
1 Thr558 lies buried in the FERM-C-terminal tail interface, and its phosphorylation is expected to favor domain dissociation. PIP 2 binds to a site between lobes F1 and F3, and has been proposed to confer subtle conformational changes that favor The sequence for αC is folded back (runs right to left) to indicate its register with the αB helix. Helical regions are indicated by a yellow coil, and the β1 strand of the C-terminal tail by a red arrow. The a and d positions of the coiled-coil heptad repeat are shown with orange and cyan backgrounds, respectively. 16 These positions interact with the other helix of the coil, as shown. Residues that are disordered in both Sfmoesin structures are shown with lower case italics. Sequence numbering corresponds to that of Sfmoesin, and the asterisks indicate invariant or highly conserved residues. Sites sensitive to trypsin digestion in the radixin α-helical domain (black arrows), and positions in human merlin associated with cancer (purple arrows) are indicated. Sequences used are as follows: human merlin (HsMerlin), SwissProt accession no. P35240; human radixin (HsRadixin), P35241; human ezrin (HsEzrin), P15311; human moesin (HsMoesin), P26038; and D. melanogaster moesin (DmMoesin), GenBank accession no. NP _ 996392. dissociation of the interface, for this site is not obviously masked in the dormant protein. 25 Although merlin is expected to have the same domain architecture as ERM proteins, 4, 26 it is activated differently via phosphorylation at other sites, and the self-associated, closed form is thought to be responsible for its tumor suppressor activity. 27 Here, we report the structure of the full-length, dormant monomeric moesin endogenous to ovarian Spodoptera frugiperda cells (Sfmoesin), the ERM protein expected to play an essential role in establishing polarity in insect embryos. 28 The central α-helical domain is seen to contain three helices, including a striking 70 Å anti-parallel coiled-coil, that form extensive, unanticipated and functionally important interactions with the FERM domain. We argue that this structure provides a complete and relevant model for the dormant state of ERM proteins, and for what is thought to be the relevant tumor suppressor state of merlin.
Results

Overall structure
Sfmoesin was purified with yields of 0.5 mg/l from ovarian insect cells, and is a stable monomer as determined by gel-filtration chromatography. The cDNA sequence we determined corresponds to a protein of 575 residues, having 83% identity with (F1, F2 and F3) are colored cyan and the C-terminal domain is colored red. The β1 strand of the C-terminal domain is contributed by a crystal-packing interaction. (b) The 2.1 Å Sfmoesin structure. The α-helical domain (yellow) folds into three extended helices (αA, αB and αC), each containing elements that pack against the FERM domain. The αB and αC helices form an anti-parallel coiled-coil. (c) In the 3.0 Å structure, 67 more residues of the ∼70 Å αB/αC coiled-coil are revealed.
Drosophila moesin and ∼60% identity with human ERM proteins. The most variability occurs within residues 315-500, which spans most of the α-helical domain and the beginning of the C-terminal tail ( Figure 1 ). Within this region, Sfmoesin and human ERM proteins have <25% sequence identity. Residues 299-461 have significant coiled-coil probability, 29 with hydrophobic residues dominating at positions a and d of the heptad repeat (Figure 1(b) ).
We determined two closely related crystal structures of Sfmoesin at 2.1 Å and 3.0 Å resolution ( Table 1 ; Figure 2 ), with the lower-resolution structure revealing a much larger portion of the α-helical domain. In addition to the expected tri-lobed FERM domain and C-terminal tail interaction, the α-helical domain is revealed to consist of three extended helices (αA, B and C). The first helix folds back under lobe F1, as has been observed in several earlier structures of the open form of ERM-merlin proteins (Figure 3 (a)), and is followed by helices that form the outgoing (αB) and incoming (αC) segments of a 70 Å antiparallel coiled-coil. The N terminus of αB (residues 328-350) is not paired with αC, and instead uses the hydrophobic residues of its heptad repeat to interact with a highlyconserved surface on the F1 lobe (Figures 1(b) and 4). Comparison of the moesin coiled-coil with those from other proteins demonstrates that it has standard geometry, including the N-terminal portion of αB that interacts with F1 ( Figure 3) .
Although the αB-αC loop of the α-helical domain is not observed, there is sufficient room in the crystal lattice for the missing residues to form a helical hairpin, and there is also no possibility for the formation of a crystalline dimer mediated by the coiled-coil ( Figure 5(b) ). An examination of B-factors shows that the FERM domain is very well ordered, on the whole, as are the segments of the α-helical domain that anchor its αA, αB and αC helices to the F1 lobe ( Figure 5(b) ). However, B-factors for residues in the coiled-coil increase steadily as their distance from the F1 lobe increases, rising to >140 Å 2 at the termini. Nevertheless, helical electron density for the backbone of these residues is unambiguous. C-terminal to the αC helix (ending with Thr460), a "linker region" threads through the cleft formed between lobes F1 and F3, with residues 461-465 forming a short 3 10 -helix and residues 465-472 adopting the conformation of a type II polyproline helix. The visible density ends at residue 472, and 17.9 (16.8) 18.1 (26.9) R free e 21.5 (22.9) 24.9 (33.5) R final f 17.6 (16.3) 18.4 (24.7) a Numbers in parentheses correspond to the highest resolution shell of data; data set A, 2.74-2.6 Å; data set B, 2.18-2.10 Å; data set C, 3.11-3.00 Å.
, where I(hkl) is the mean intensity of i reflections after rejections. A -1.0 I/σ I cutoff was applied to data set C.
c Numbers in parentheses correspond to the highest resolution shell of data; data set B, 2.15-2.10 Å; data set C, 3.08-3.00 Å. (hkl) | ; no I/σ cutoff was used during refinement.
e A portion (5%) of the truncated data set was excluded from refinement and used to calculate R free . f Final R-factor after the last rounds of refinement, when all reflections were used. begins again at Glu486, the first residue of a β-strand associated with lobe F3 that defines the start of the C-terminal tail domain. The intervening disordered loop is enriched with acidic residues in ERM proteins (Figure 1(b) ).
Interactions of the α-helical domain with the FERM domain
The central α-helical domain of moesin forms multiple, extensive contacts with highly conserved surfaces of the FERM domain ( Figure 4 ). One surface, formed by both the F1 and F2 lobes, interacts with the αA helix, and two other faces of F1 stabilize and give direction to the αB/αC coiled-coil: one face interacts with the N-terminal portion of αB and the other provides a specific docking site for the residues at and after the Cterminal end of helix αC. We refer to these two interaction surfaces are as the launching and landing pads for the antiparallel coiled-coil, respectively. The contacts that the α-helical domain and the subsequent linker region ( Figure 1 ) form with the FERM domain bury 3800 Å 2 of total accessible surface area.
The interactions of αA are bipartite ( Figure 6(a) ). The highly conserved N terminus of αA (residues 298-313) forms extensive hydrophobic interactions with a continuous surface of F1 and F2, wherein the side-chain of Ile94 (in F2) is buried in a hydrophobic pocket formed by Val302, Met305, Lys306 and Ala 309 (in αA), while the side-chain of Met305 (αA) is buried in a pocket formed by Arg40 and Trp43 (in F1) and His465 (linker region). In the second interaction region, the C terminus of αA and the subsequent αA-αB loop form primarily electrostatic contacts with F2. The basic side-chains of Arg184, Lys316, Arg320, Arg332 (all invariant or highly conserved) cluster together, and are in close proximity to the acidic side-chains of Glu96, Glu185 and Glu326 (also highly conserved). The backbone of the αA-αB loop is disordered in the 3.0 Å structure ( Figure 5(b) ), and has relatively high B-factors in the 2.1 Å structure, suggesting marginal stability of these interactions.
The launching pad interaction for the αB/αC coiled-coil is formed by the hydrophobic face of the αB helix just before the coiled-coil, which abuts the αA helix of the F1 lobe ( Figure 6(b) ). The highly conserved residues that make up this surface, Figure 3 . Comparison of the Sfmoesin α-helical domain with active ERM domain structures and other coiled-coil domains. (a) The structures of "activated" merlin, radixin, and moesin (PDB entries 1ISN, 1J19, 1E5W, respectively) superimposed on the 2.1 Å structure of Sfmoesin, showing that the αA helix does not alter its orientation greatly upon activation. (b) The Rad50 coiled-coil (PDB entry 1L8D) superimposed on that of the 3.0 Å structure of Sfmoesin in the same orientation as in (a). In this structure, Rad50 is dimerized through a hook-like structure at the turn of the coiled-coil. 48 (c) Superposition of the methyl-accepting chemotaxis protein coiled-coil (PDB entry 2CH7).
49 This coiled-coil is half of an antiparallel four-helix bundle. Note that the N-terminal segment of Sfmoesin αB, which does not participate in a coiledcoil with αA, maintains proper coiled-coil geometry. Superpositions are the optimal fits reported by a search of the PDB using the DALI server.
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Tyr340, Leu344 and Met347, occupy the d-a-d positions of the coiled-coil heptad repeat. Specific hydrogen bonds are formed between the side-chain of Gln337 (αB) and the backbone of Glu15 (F1), the side-chain of Arg343 with backbone carbonyl groups of residues 35 and 36, and the Tyr340 hydroxyl group with the side-chain of Asp13.
The landing pad interactions involve both the end of the αC helix and the linker region ( Figure 6(c) ). The amino group of Lys35, conserved as either Lys or Arg among ERM-merlin proteins, caps the end of the αC helix. Lys27 and Asp31, which form an invariant salt-bridge within F1, coordinate the buried hydroxyl group of Thr461. His465 forms a hydrogen bond with the side-chain of Asp301 in the first turn of the αA helix, joining the two ends of the α-helical domain. The side-chain of His466 packs in a conserved hydrophobic pocket formed by Lys27, Phe30, Val42 and Leu61. Subsequently, the sidechain of Val467 packs against F3, and Glu469 forms two hydrogen bonds with the backbone nitrogen atoms of residues 61 and 62. Invariant moesin residues Glu289 and Arg293 (F3) together form a salt-bridge as well as three hydrogen bonds with the backbone of residues 465, 466 and 468.
Comparisons with previous ERM structures
Earlier structures of truncated/activated ERM proteins have included only the first 49, 27 and 14 residues of the α-helical domain (Figure 3(a) ). The intact Sfmoesin αA helix stays more tightly associated with the FERM domain than the others, possibly because they are missing subsequent residues that, as in Sfmoesin, would help restrain the C-terminal end of this helix.
Overlay of Sfmoesin with the radixin·IP 3 complex demonstrates that the IP 3 binding site is sterically blocked by the linker region ( Figure 7) . Moreover, the disordered loop joining the linker region to the Cterminal tail is intensely acidic in ERM proteins (Figure 1(b) ). Thus, the linker and subsequent loop dramatically lower the electrostatic potential of a surface of the FERM domain (Figure 7(b) and (c)) believed to associate with negatively charged membranes in the active form of ERM proteins. Because the 2 h soak of IP 3 into the Sfmoesin crystals used for the low-resolution data set showed no electron density for this ligand, IP 3 alone under the crystal-harvesting conditions is insufficient to displace the linker and subsequent loop, rendering them an effective mask for PIP 2 binding. This appears to conflict with a recent report that PIP 2 binding is a prerequisite for C-terminal domain phosphorylation in ezrin. 30 However, IP 3 may be a poor mimic for PIP 2 in the context of a phospholipid bilayer.
Finally, the Sfmoesin structure confirms the structure and register of the β1 strand in the C-terminal tail ( Figures 1, 2 (b) and 7(a) and (b)), which is domain- Figure 5 . Crystal packing interactions and mobility of the α-helical domain. (a) Stereo view along the crystallographic 2-fold axis of a D 3 center in the crystals of the 3.0 Å structure. Each asymmetric unit in the cluster is colored uniquely. In this structure, differences in lattice packing tilt the αB/αC coiled-coil region by 7°with respect to the 2.1 Å structure, allowing it to form crystal contacts with a 2-fold-related coiled-coil via the side-chains of . Only residues 400-409 are missing from its helical turn. This structure eliminates the possibility of a dimer mediated by the coiled-coil in the crystalline lattice. (b) Temperature factors as a function of residue position in the 2.1 Å and 3.0 Å structures of Sfmoesin. The regions of the α-helical domain that contact the FERM domains are as stable as the FERM domain, while those at greater distances from the ERM domain have gradually increasing mobility. The change in crystal contacts between the two structures orders more of the αB/αC coiled-coil in the low-resolution structure, and disorders part of the αA-αB loop (residues 312-325). Residues colored with white carbon atoms indicate side-chains that are disordered or exist in multiple conformations in the 2.1 Å crystal structure. (b) The launching pad involves the hydrophobic face of αB and a highly conserved surface of the F1 lobe. Met347 is analogous to the site of tyrosine phosphorylation in ezrin, 35, 36 which leads to activation of ezrin in response to growth factor stimulation. Mutation of the residue analogous to Leu344 to proline in merlin is associated with NF2. 39 Both modifications in the context of the Sfmoesin structure likely disrupt this interface. (c) The landing pad is formed by the end of the αC helix and the linker region. Contacts between the linker region and the F1 lobe are dominated by backbone-side-chain interactions, possibly explaining the lack of strong sequence conservation in this region of the α-helical domain. Mutation of the residue analogous to Trp43 and residues in the F1 αA helix in merlin are also associated with NF2. 39, 51 These changes likely disrupt the observed interdomain contacts.
swapped in the human moesin FERM/C-terminal domain complex and masks the ICAM-2 peptide binding site observed in the radixin-ICAM-2 complex. 22 The intact path of this strand to the remainder of the C-terminal domain is therefore fully defined in Sfmoesin. Sequence comparison suggests Figure 6 (legend on opposite page) that all ERM-merlin proteins will share an analogous β-strand interaction with the F3 domain ( Figure 1(b) ).
Discussion
A model relevant to the entire ERM-merlin family
The structure of the endogenous, intact Sfmoesin reported here provides a very important advance in the study of ERM proteins, as it defines the complete dormant state of these proteins. For merlin, it has been postulated that the analogous closed conformation is responsible for tumor suppressor activity. 27 In this conformation, the Sfmoesin structure demonstrates that there are extensive interactions of the central α-helical domain with the FERM domain, indicating that the α-helical domain plays a surprisingly active role in masking additional ligand-binding and activation sites.
Conservation in other ERM-merlin proteins of the arrangement of the Sfmoesin αA, αB and αC helices in the α-helical domain is supported strongly by sequence conservation and biochemical studies. Unlike the αA helix, the coiled-coil portion of αB and αC (but not the αA-αB or αB-αC loops) has an almost perfect heptad repeat. Our structure also easily accommodates the seven residue insertion found in human radixin, ezrin and merlin proteins within or near the αA-αB loop (Figure 1(b) ). In addition, limited proteolysis of the recombinant isolated α-helical domain of human radixin show rapid cleavage at residue 330 followed by cleavage at residue 351 to yield a relatively stable fragment spanning residues 352-469. 17 The first cleavage site corresponds to the highly mobile αA-αB loop (Figure 4(b) ) and the second matches the position within αB just before the start of the coiled-coil segment. The stable proteolytic fragment is thus a reasonable match with the αB/αC coiled-coil region of the Sfmoesin structure ( Figure 1(b) ). This correlation leads to the rather remarkable inference that, even in the absence of contacts with the FERM domain, there are features intrinsic to the α-helical domain that partition it into the three distinct helices observed in the Sfmoesin structure.
Surfaces of the FERM domain that contact the α-helical domain are remarkably well conserved (Figure 4 ), supporting a biological role for these interactions. Interdomain contacts include the docking of αA onto the FERM domain via Met305, Lys306 and Ala 309 ( Figure 6 (a)), as observed in earlier crystal structures of activated ERM-merlin proteins ( Figure 3(a) ). The N terminus of αB from the α-helical domain interacts with a nearly invariant surface of the F1 lobe with no previously ascribed function. The helical domain αC helix is followed by a stop signal (T/STPxxxxxxE) conserved among moesin proteins that also contains two residues (the second Thr and the ultimate Glu) that form specific interactions with lobe F1 (Figure 6 (c)). Although ezrin, radixin and merlin have a polyproline stretch in this region (Figure 1(b) ), this is nevertheless compatible with the salient features of the Sfmoesin linker region. Specifically, the most important interactions made by the "spacer" residues (given as 'x' above) as they wind toward the IP 3 binding site are made primarily by their main-chain atoms ( Figure 6(c) ). In addition, the backbone conformation of the linker is superimposable with a polyproline helix. Finally, it seems likely that the conserved, highly acidic region joining the linker region and the C-terminal domain (Figure 1(b) ) in ERM proteins could play a functional role in hindering PIP 2 and membrane interactions until the α-helical and/or C-terminal domains become displaced.
The α-helical domain in activated ERM-merlin proteins
Biochemical studies of ERM-merlin proteins and the Sfmoesin structure now support the idea that the α-helical domain can adopt a variety of physiologically relevant conformations, ranging from the relatively condensed, inactive structure that we observe in Sfmoesin, to a relatively protected one in which the domain is dissociated from the FERM domain yet forms two or three helices that retain the observed αB/αC coiled-coil interaction, to a fully extended helix. The existence of the latter two states is supported by limited proteolytic digestion and biophysical studies of the isolated α-helical domain of radixin, and the activated structure of moesin. 17, 31 For full activation of ERM proteins, large conformational changes are needed to expose various regulatory sites, including that for PIP 2 , which is masked by the linker region ( Figure 7 ). This direct model for activation is in contrast to a previous model, wherein it was speculated that PIP 2 binding led to activation via relatively subtle conformational changes. 25 Unraveling the αB/αC coiled-coil observed in the dormant state also appears to be a prerequisite for gaining access to the buried hydrophobic residues that compose the A-kinase anchoring sites reported for ezrin and merlin. 32, 33 Consistent with this, binding of merlin to RIβ occurs only in forms of merlin that mimic the open state (e.g., C-terminally truncated). Thus, the putative "switchblade-like" opening of the αB/αC coiled-coil into an extended helix may represent yet another functionally relevant unmasking event. The interconversion of helical and non-helical regions required for the proposed switchblade-like opening of the helical domain has good precedent, such as the pH-triggered conformational change observed in hemaglutinin-mediated membrane fusion. 34 Conversion of the αB/αC coiled-coil to a fully extended state upon activation is supported also by biophysical studies of the isolated helical domain of radixin in which this region appears to form an unusual monomeric 240 Å long helix. 17 This seems possible, given the strong helical potential of the αA-αB and αB-αC loops (Figure 1(b) ) and the fact that the 50 residues of the α-helical domain present in an activated moesin FERM structure continue as an uninterrupted helix that leaves the FERM domain in the direction of αA, 31 rather than breaking at the αA-αB turn, as is observed in Sfmoesin (Figure 3(a) ). Conversion to this extended form is likely to be stabilized by ligands that favor binding to a single amphipathic helix, such as AKAPs.
Until now there has been no concrete model for how Tyr353 phosphorylation of ezrin contributes to its activation. 35, 36 The structurally equivalent residue in Sfmoesin (Met347) is buried at the end of the launching pad of αB (Figure 6(b) ) and it is reasonable to assume that Tyr353 in ezrin interacts similarly. Phosphorylation of Tyr353 in ezrin would be expected to strongly favor release of the α-helical domain from the FERM domain.
Finally, our studies provide insight into the structures of the dormant ERM homodimers that, when compared to dormant monomers, have indistinguishable patterns of limited proteolysis. 37 We propose that in these dimers, the αB-αC turn does not exist, and instead two molecules associate via a fully-extended αB and αC helix that forms an intermolecular antiparallel coiled-coil and allows the C-terminal tail domain of each chain to interact with the FERM domain of the other chain. In this way, exactly the same launching and landing pad contacts would be maintained. Consistent with this model, the αB-αC turn consists of exactly seven residues (Figure 1(b) ), so that the heptad repeat would be perfectly maintained in such a domainswapped dimer. While the physiological relevance of dormant homodimers is unknown, this structural arrangement could be present in the ezrinmerlin (and other) heterodimers that likely do exist in vivo. 38 An explanation for enigmatic mutations in the tumor suppressor merlin Many of the missense mutations associated with NF2 27,39 defied explanation when mapped onto earlier atomic structures of ERM-merlin proteins. When mapped on the tertiary structure of Sfmoesin (Figure 1(b) ), the structural impact of many of these merlin mutations becomes clear, lending further support to the biological relevance of the α-helical domain contacts. Of the non-truncating mutations of merlin that are known to be pathogenic in cells, 16 are found in the F1 lobe, nine in F2, six in F3, ten in the α-helical domain and seven in the C-terminal domain. Of those that are purely missense (not insertions or deletions), ten are in F1, four are in F2, four are in F3, ten are in the α-helical domain, and six are in the C-terminal tail. The preponderance of disruptions in the F1 lobe and the α-helical domain implies an important role for these domains in maintaining merlin in a stable, closed, active form. The F1 lobe αA helix, straddled by the αB and αC helices of the α-helical domain (Figure 6 ), is particularly rich in NF2-associated disruptions. Also, the F1 lobe αA-β3 loop, with residues interacting with both the αA helix and the landing pad, is relatively rich in mutations. Mutations identified in the α-helical domain of merlin are dispersed throughout, but some are found in the highly conserved N terminus of αA: at Leu323 (L339F in merlin), a residue that helps to stabilize the αA-αB loop ( Figure 6(a) ), and at Leu344 (L360P), a buried αB residue in the launching pad interface (Figure 6(b) ). This remarkable correlation between sites of diseasecausing merlin mutations and sites involved in stabilizing interactions between the α-helical and FERM domains supports the conclusion that the closed form of merlin is required for its tumor suppressor activity.
An active regulatory role for the α-helical domain
The crystal structure of the FERM-C-terminal tail domain complex of human moesin showed that the complex is held together by five, largely independent, interacting parts. 4 We can now extend this model to include the launching and landing pads of the central α-helical domain, which together with the coiled-coil interaction provide the sixth, seventh and eighth points of interaction that can be modulated independently to influence the net affinity of the masking interactions. Interestingly, these interaction points with the FERM domain are, apparently, purposefully of lower affinity than they could be. For example, ICAM and EBP50 peptides have conserved sequence features not present in the ERM sequences, and they bind to their respective sites on the FERM domain much more tightly in trans (nanomolar affinities) than does the tail domain in cis. Such distributed binding involving many purposefully medium or low-affinity interactions creates a net high-affinity interaction via the chelate effect, 40 but that can, in principle, have its affinity fine-tuned to many different levels by a wide variety of effectors. In addition to the known effectors discussed above, the interactions of the α-helical domain allow speculation that another modulator of activation could be the binding of SH3 domains to the polyproline sequences that fill the F1-F3 cleft in ezrin, radixin and merlin. In accordance with this idea, the focal adhesion kinase FERM domain, although distantly related to ERM proteins and lacking an α-helical domain, has a regulatory linker region C-terminal to the FERM domain that occupies the cleft between its F1 and F3 lobes. The linker forms a β-strand interaction, analogous to but opposite in orientation to the β1 strand of the Sfmoesin C-terminal domain, and a polyproline helix, bound to F3, that can be sequestered by the SH3 domain of Src. 24 We conclude that the central α-helical domain is not just a passive structural feature that is important for facilitating effective cytoskeletal-membrane linkage once the activated proteins are generated. Instead, it is actively involved in masking, burying ∼2000 Å 2 of FERM domain surface area, about 75% of that buried by the C-terminal tail interaction. Together, the central and C-terminal tail domains bury 4700 Å 2 , which is 25% of the accessible surface area of the FERM domain and mask directly all known sites for activating ligands or modifications (i.e. the PIP 2 binding site and phosphorylation sites Thr558 or ezrin Tyr353) or docking targets (EBP50/NHERF, ICAM and actin). As alluded to before, 4 and extended here from five to eight points of interaction, we propose that ERM proteins are subject to a rheostatlike mechanism for a graded regulation of activation. Multiple regulatory pathways that impinge on the ERM proteins could be combined and/or integrated to allow for different levels of release of the coiled-coil domain, depending on their sites of interaction, and hence unmasking of ligand-binding sites. Finally, our studies have now yielded an important image that fully describes the structural components involved in the closed form of ERM-merlin proteins. Such information will be exceptionally useful in the design and interpretation of a new generation of experiments aimed at unraveling the activation mechanisms of ERM proteins and to better understand the tumor suppression mechanism of merlin.
Materials and Methods
Purification
The endogenous moesin protein from Sf ovarian cells was purified by the protocol used to purify G protein-coupled receptor kinase 2 (GRK2).
41 Except in the first purification, wherein Sfmoesin was mistakenly purified instead of GRK2, Sfmoesin-containing fractions were identified by Western analysis using a rabbit polyclonal antibody (a gift from D. Kiehart, Duke University) at a 1:40,000 dilution. The final purification step was over two tandem S200 gelfiltration columns (Amersham Pharmacia Biotech) equilibrated in 20 mM Hepes (pH 7.8-8.0), 200 mM NaCl, 2 mM DTT. The protein eluted with an expected molecular mass of 74 kDa based on comparison with Bio-Rad gel filtration standards. The resulting homogeneous moesin was concentrated to 4.75 mg/ml. The total yield was 0.12-0.45 mg/l of Sf cell culture.
Crystallization
Sfmoesin crystals were grown by the hanging-drop, vapor-diffusion method using the conditions used for GRK2, 42 with 100 mM Hepes (pH 7.8) as the buffer for the well solution. For harvesting, cryoprotectant solution (25% (v/v) PEG400, 15% (w/v) PEG 8K, 50 mM phosphoserine (pH 7.5), 800 mM NaCl, 800 mM urea, 1 mM DTT, 22 mM Hepes (pH 8.0) and 22 mM Hepes, pH 7.8) was added 1 μl at a time into the hanging drop, and then crystals were transferred into 100% cryoprotectant solution. The crystals were then flash-frozen in liquid nitrogen on nylon loops (Hampton Research).
Diffraction data collection
A preliminary 3.5 Å data set (data set A) was collected at the Advanced Light Source (ALS) on a Quantum 210 CCD detector (ADSC) at beam-line 8.3.1 and was used for the initial structure determination. A higher resolution data set (data set B) was later collected at the Advanced Photon Source (APS) on a Quantum 4 CCD detector (ADSC) at beam-line 17-ID. Lastly, a 3.0 Å data set (data set C) was collected at APS beam-line 19-BM from a crystal soaked for 2 h in harvesting solution supplemented with 1 mM IP 3 . Data were indexed, integrated and scaled using HKL2000. 43 The crystal soaked in IP 3 had significantly different cell constants (>1% change), suggesting a conformational change. Unit cell parameters and data collection statistics are summarized in Table 1 .
Identification of moesin by mass spectrometry
Sfmoesin was purified using the scheme used for GRK2, had a similar apparent molecular mass (74 kDa for Sfmoesin, 80 kDa for GRK2) and crystallized under conditions identical with those used for GRK2. However, molecular replacement using the structure of GRK2 failed to yield a solution. To verify the identity of the crystallized protein, a drop of the protein solution (roughly 5 μg) was taken from the hanging drops used for crystallization, subjected to SDS-PAGE (10% polyacrylamide gel), and then subjected to trypsin digestion in-gel followed by matrix-assisted laser desorption/ionization mass spectrometry at the Institute for Cellular and Molecular Biology Protein Core Facility (UT Austin). Four abundant peptide peaks were generated, and their resulting masses were best matched to Drosophila melanogaster moesin (residues [29] [30] [31] [32] [33] [34] [35] [36] QLFDQVVK; [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] EVWFFGLQYTDSK; [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [239] [240] [241] [242] [243] [244] [245] [246] [247] IGFPWSEIR) , suggesting that the crystallized protein was in fact the moesin protein endogenous to S. furgiperda, which had not been sequenced.
Structure determination and refinement
Phases were determined by straightforward molecular replacement using the structure of the FERM/C-terminal tail complex of human moesin (PDB code 1EF1) as a search model, reflections from data set A and the program PHASER from the CCP4 suite. 44 The resulting model was refined with simulated annealing in CNS, 45 and then REFMAC5. 46 The sequence of D. melanogaster moesin was used for initial model building. The high resolution of data set B permitted "sequencing by electron density" in the best-resolved regions, and refinement was continued in REFMAC5. Upon sequencing of the Sfmoesin cDNA (see below), the refinement was completed (Table 1) . At an R-factor of 17.9%, and R free of 21.5%, the use of R free was discontinued so that all reflections could be used during the last few rounds of refinement. The final model for data set B contains residues 3-364, 442-470 and 486-575 (out of 575 total) and has R final = 16.3%. Difference Fourier analysis between data sets B and C revealed no significant electron density that might correspond to IP 3 , which was soaked into the crystals used for data set C. However, these maps revealed that significantly more of the α-helical domain was ordered in data set C, and so an atomic model was refined using this data set as well. The final model from data set C contains residues 3-320, 326-399, 410-472, and 486-575 . The different unit cell constants for data set C (Table 1) presumably derive from the 2 h soak in harvesting solution (as compared to several minutes for data set B). In the 3.0 Å structure, changes in crystal contacts disorder the αA-αB loop (residues 312-325) and lead to the formation of a new crystal contact stabilizing the αB/αC coiled-coil ( Figure 5(a) ). In both structures, the backbone of residue 252 is in a disallowed region of the Ramachandran plot (Table 1) . This residue, conserved as Asp or Glu in all ERM-merlin proteins, is in the i+1 position of a type II′ β-turn (normally occupied by glycine), has good electron density, and the analogous residue in other ERM structures has the same conformation. The backbone nitrogen atom of Asp 252 forms a hydrogen bond with residue 486, the first visible residue of β1 in the C-terminal tail domain.
Sequencing of Sfmoesin
To determine the sequence of Sfmoesin, a portion of the highly conserved FERM domain was amplified using PCR with degenerate oligonucleotide primers followed by 5′ and 3′ RACE to complete the flanking sequences. Total RNA was isolated from Sf9 cell cultures using Trizol (Invitrogen). First-strand synthesis was performed using random hexamer primers and Multiscribe (Applied Biosystems) reverse transcriptase. Using this template DNA, PCR was performed using degenerate primers previously described for cloning of D. melanogaster moesin, 47 as well as degenerate primers based on the Sfmoesin protein sequence determined by mass spectrometry. Once the sequence of the FERM domain was obtained, 5′ and 3′ RACE were performed to obtain flanking sequences using the GeneRacer system (Invitrogen) following the manufacturer's instructions.
Protein Data Bank accession numbers
Coordinates and intensities corresponding to data sets B and C are deposited with the Protein Data Bank under the accession numbers 2I1J and 2I1K, respectively. 
Structural Basis of Integrin
SUMMARY
Regulation of integrin affinity (activation) is essential for metazoan development and for many pathological processes. Binding of the talin phosphotyrosine-binding (PTB) domain to integrin b subunit cytoplasmic domains (tails) causes activation, whereas numerous other PTB-domain-containing proteins bind integrins without activating them. Here we define the structure of a complex between talin and the membrane-proximal integrin b3 cytoplasmic domain and identify specific contacts between talin and the integrin tail required for activation. We used structure-based mutagenesis to engineer talin and b3 variants that interact with comparable affinity to the wild-type proteins but inhibit integrin activation by competing with endogenous talin. These results reveal the structural basis of talin's unique ability to activate integrins, identify an interaction that could aid in the design of therapeutics to block integrin activation, and enable engineering of cells with defects in the activation of multiple classes of integrins.
INTRODUCTION
Integrins are found throughout the animal kingdom, where they play important roles in cell adhesion, migration, proliferation, and survival. They are membrane-spanning heterodimers of a and b subunits, both of which typically comprise a short cytoplasmic tail ($20 to 50 residues), a single transmembrane helix, and a large extracellular domain ($700 to 1000 residues). In mammals, there are 18 identified a subunits and 8 b subunits that combine to form 24 distinct heterodimers. In humans, integrins play critical roles in development and participate in the pathogenesis of heart disease, chronic inflammation, and cancer Hynes, 2002) . Many integrins are expressed with their extracellular domains in a default low-affinity ligand-binding state (the ''off state''); however, cells can change the conformation and affinity of these receptors in response to cellular stimulation in a process often termed ''integrin activation.'' This conformational change results in increased adhesion and subsequent signaling, which mediates events such as cell migration, platelet aggregation, leukocyte exit from the vasculature, and assembly of the extracellular matrix. The binding of a cytoskeletal protein called talin to the b subunit cytoplasmic tail is a common final step in the activation process (Tadokoro et al., 2003; Tanentzapf and Brown, 2006) .
Talin consists of a large C-terminal rod domain that contains bundles of a helices and an N-terminal FERM (band 4.1, ezrin, radixin, and moesin) domain with three subdomains: F1, F2, and F3 Papagrigoriou et al., 2004; Rees et al., 1990) . Talin colocalizes with integrins (Horwitz et al., 1986 ) and binds to F-actin and actin-binding proteins (reviewed in Critchley, 2005) , thus linking the actin-cytoskeletal network to the extracellular matrix. The F3 subdomain of the FERM domain contains the highest affinity integrinbinding site for integrin b tails and is sufficient to activate integrins (Calderwood et al., 2002) . A partial view of this interaction was obtained in a crystal structure of the F2 and F3 domains of the talin FERM domain in complex with a 12 residue fragment ( 739 WDTANNPLYDEA 750 ) comprising $25% of the b3-integrin tail . That work confirmed that the F3 domain has a phosphotyrosine-binding (PTB) domain fold and that its interaction with integrins strongly resembles the interaction of other PTB domains with peptide ligands . Several other PTB domains bind to b3 in a similar fashion to talin , but only talin has exhibited the capacity to activate integrins. Thus, we reasoned that additional unique features of the integrin/talin interaction enable talin to cause activation. Indeed, nuclear magnetic resonance (NMR) spectroscopic evidence has suggested an interaction between talin F3 and the membrane-proximal (MP) btail region Vinogradova et al., 2002) that is important for activation (Hughes et al., 1995; Ulmer et al., 2003) . However, such an interaction has not been directly observed. Here, we provide the first atomic-level description of the interaction between talin and the MP region of the b3-integrin cytoplasmic domain. Structure-based mutagenesis shows that disruption of the newly identified interactions blocks integrin activation in cells while retaining binding to the membrane-distal (MD) region of b3. These results define the talin/integrin interactions that lead to integrin activation and explain why talin's activating ability is unique among PTB-containing proteins. They also identify an interaction that is a target for the rational design of therapeutics that will block integrin activation while allowing other MD-interacting proteins to maintain their functions.
The new understanding also allows the engineering of cells or animals with selective defects in integrin activation.
RESULTS
Talin Interacts with Both the MP and MD Regions of the b3 Tail
We set out to obtain a structural explanation for the unusual ability of the talin PTB domain to activate integrins. An initial exploration of the interactions was carried out by adding various tail-derived b3-integrin peptides to the F3 subdomain of talin while monitoring the chemical shift perturbations in 1 H-15 N-HSQC NMR spectra. The peptide sequences and the nomenclature used are set out in Figure 1A peptide primarily causes chemical shift perturbations in strand S5 (de Pereda et al., 2005) . The chemical shifts for the MP peptide show that it interacts with a site on F3 that is distinct from the MD-binding site (Figure 1) . The new perturbations found in the MPbinding site mainly arise in residues that form a loop between the first and second b strands (S1 and S2) of the F3 structure. Residues 358 and 359 of F3 are also perturbed, presumably due to the b-tail residue W739 that is included in both the MP and MD peptides and binds tightly in a pocket on the surface of F3.
NMR studies of the interaction with full-length b3 cytoplasmic tails were more challenging. The off rates of the complex correspond to an ''intermediate exchange'' regime, with peaks broadening and disappearing rather than changing position. It was possible, however, to define perturbed residues by plotting the percentage decrease in peak height upon addition of the peptide (Figures 1D and S1 ). The perturbed residues are essentially the sum of those affected by the MD peptide and the MP peptide (Figures 1 and S1 ). The b3-tail/talin F3 interactions can thus be considered in two parts, with one corresponding to the previously defined interaction at the MD site and the other corresponding to the MP site. The limited solubility of the full-length b3 tail meant that it was not possible to produce a 1:1 complex at the concentrations used. This, together with exchange broadening of lines, made the b3 tail an unsuitable ligand for studying the structure of the talin/integrin complex by NMR at atomic resolution.
We have, however, previously shown that a peptide segment from phosphatidylinositol phosphate kinase type Ig (PIPKIg) binds in a similar manner to the b3-integrin peptide in the MD site (de Pereda et al., 2005) . These data are shown again here for comparison ( Figures 1D and S1 ). Both peptides bind to talin F3 and form a b strand followed by a reverse turn, but the PIPKIg peptide binds with much higher affinity in a slow-exchange NMR regime, and a 1:1 complex is readily achieved. Critically, W739 from the b3 tail and W642 from the PIPKIg peptide occupy essentially identical positions and adopt identical main-chain and side-chain torsion angles, each binding in a deep pocket on the talin protein surface (de Pereda et al., 2005; . This strong similarity led us to believe that a synthetic chimeric peptide comprised of b3-integrin tail residues on the N-terminal side of the critical tryptophan and PIPKIg residues on the C-terminal side would yield a peptide ligand with higher affinity and better solubility that would be suitable for high-resolution studies of the F3-MP interaction. The sequence of the designed chimeric peptide is shown in Figure 1A . NMR experiments showed that this chimeric peptide does indeed bind to talin and forms a tight, highly soluble 1:1 complex. Moreover, comparison of the protein-backbone chemical shifts in the bound and unbound states indicates that the residues affected by the chimeric peptide are essentially the sum of residues affected by the MP-integrin peptide and those affected by the PIPKIg peptide (Figures 1 and S1 ), supporting the idea that the chimera is suitable for structural studies of the F3-MP interaction.
The Structure of the Talin F3/Peptide Complex Reveals a Binding Interface with the MP Site The structure of the complex was calculated from NMR data using a total of 2187 experimental restraints, 138 of which were unambiguous intermolecular nuclear Overhauser effects (NOEs; Table S1 and Figure 2 ). As expected, the PIPKIg-derived portion of the peptide binds in a manner very similar to that seen in the crystal structure (de Pereda et al., 2005) ; the SPLH sequence (residues 742-745) forms a reverse turn, and residues 739-741 create a b strand that augments the b sheet formed by strands S5-S7 from talin ( Figure 2) . Importantly, the pivotal tryptophan residue (W739) that connects the two sequences in the chimera aligns closely with the same residue in the crystal structure of the b3-tail complex (GarciaAlvarez et al., 2003; Figure 2C ). This strongly suggests that residues 716-739 of the b3 tail are free to adopt their native orientation in the F3 complex. The extended nature of the complex and the relative rigidity of the F3 domain are consistent with the notion that the MD site and the MP site behave relatively independently ( Figure 2B ). Thus, any differences between the native integrin peptide and the chimeric peptide are restricted to the MD site. The structural and functional implications of differences between the binding of the PIPKIg peptide and the b-tail MD site have been discussed previously (de Pereda et al., 2005) .
The new structure reveals important novel contacts between the MP region of b3 and talin. Specifically, the b3-derived portion of the peptide forms an a helix between H722 and R736. This helix lies across strands S1-S2 and S6-S7 of the talin F3 domain and buries two phenylalanine residues of the b3 tail (F727 and F730). Of the 138 intermolecular NOEs used in the structure calculation, 57 define the MP integrin/talin interface. The majority of these involve the two phenylalanine residues F727 (23 NOEs) and F730 (18 NOEs) . The hydrophobic talin residue L325 appears important for this interaction, and 7 NOEs were identified between this residue and the phenylalanine side chains (see Figure S2 ). The calculated structure is consistent with the chemical shift changes in the F3 domain observed during NMR titration experiments ( Figure S1 ).
There is a propensity for residues 722-732 of the free b3 peptide to form an a-helical structure since the a-proton chemical shifts of these residues are consistently downfield from random-coil values. Binding to the talin F3 domain further increases the downfield shifts of these b-tail resonances, which indicates that the helix is stabilized in the complex (data not shown). Heteronuclear 1 H-15 N NOEs were recorded for the protein alone as well as in complex with various peptides ( Figure S3 ). The results indicate that the loop between S1 and S2 of talin F3 is stiffened by binding to the MP region of the b3 tail, which again supports the calculated structure.
Mutation of b-MP Residues that Contact F3 Diminishes the Ability of Talin to Activate Integrin aIIbb3
Contacts between talin and the MP region of the b3 cytoplasmic tail may constitute an interaction that is a key to the activation process. To test this concept, the effects of a number of designed mutations in both the b3 tail and the talin F3 subdomain were investigated. Integrin activation was assessed using the antibody PAC1 and flow cytometry as previously described .
The effects of mutating F727 and F730, which both make intimate contact with F3, were investigated using a mutant integrin aIIb subunit, R995A. When paired with a wild-type (WT) b3 subunit, the assembled integrin is in an activated state in transfected cells ( Figure 3A) , which is consistent with previous reports (Hughes et al., 1996) . The activated state is dependent on endogenous talin, as shown by the decrease or abolition of ligand binding when the influence of talin is reduced either by talin knockdown or by a mutation in the b tail (Y747A) that disrupts talin binding (Tadokoro et al., 2003;  Figure 3A ). When aIIb(R995A) was paired with b3(F727A) or b3(F730A), b3 mutants designed to disrupt the F3-MP interaction, the activating effect of the aIIb(R995A) mutation was dramatically reduced ( Figure 3B ).
Mutation of F3 Residues that Contact the b Tail Diminish the Ability of Talin to Activate Integrin aIIbb3
Mutations to the contact residues in talin F3 (L325R, S365D, S379R, or Q381V) were also made to see if they disrupted the F3-MP interaction. Mutants were correctly folded, as judged by their dispersed NMR spectra (data not shown), and chemical shifts induced by addition of chimeric peptide indicated that binding to the MD site was unchanged. In contrast, perturbation of contact residues in the MP region was either markedly reduced, as with F3(Q381V) and b3(F727A), or undetectable, as with F3(L325R) and b3(F730A) (Figure 4) . Transfection of cells with cDNA encoding the F2 and F3 subdomains (F23) of talin (residues 206-405) is known to activate several integrins (Calderwood et al., 2002) , but each of the four mutations diminished the ability of F23 to activate integrin aIIbb3 (Figures 3C and S4) . These results establish the biological relevance of the interactions seen between the talin F3 protein and the MP region and show that these interactions are critical for integrin activation.
Talin Mutants that Inhibit Integrin Activation
The observation that talin mutants with impaired contacts to the MP region still bind to the chimeric peptide via the MD site suggested that they might compete with and displace endogenous talin, thus inhibiting integrin activation.
To investigate this possibility, we used abPy cells from a chinese hamster ovary (CHO) cell line that expressed a talin-dependent, constitutively active chimeric integrin that was composed of the extracellular and transmembrane domains of aIIbb3 as well as the cytoplasmic tails of a6b1 (Baker et al., 1997) . We transiently transfected abPy cells with cDNAs encoding the mutant F23 constructs . The MP-contacting talin F23 mutants (L325R, S365D, S379R, and Q381V) inhibited activation, whereas the MD-contacting mutant talin F23(W359A) had no significant effect on activation levels. All data are an average of three of more measurements; error bars are standard deviations.
(L325R, S365D, S379R, or Q381V). Each of the four mutants blocked integrin activation ( Figure 3D ), a result consistent with competition between endogenous full-length talin and the activation-defective F23 mutants for binding to the b-MD site. In contrast, transfection of these cells with cDNA encoding WT F23 modestly increased activation, whereas a mutant that strongly inhibits the MD-binding site, F23(W359A), had no effect on activation, which is consistent with its markedly reduced affinity for the b tail (Table S2) .
To assess whether other PTB domains could recapitulate the dominant-negative effect of the talin mutants, abPy cells were transfected with the PTB-containing protein DOK1. As predicted, this protein inhibited integrin activation ( Figure 5A ), which is consistent with the idea that it competes with endogenous talin for the MD site but does not induce activation. Comparison of the structures of the DOK1 and talin PTB domains shows that they differ primarily in the region between strands S1 and S2 ( Figure 5B ), which is consistent with the idea that this region is vital for activation. Titration of the DOK1 PTB domain with the b3/PIPKIg peptide revealed interactions with S5, S6, and H2, which is indicative of binding to the MD region, whereas no interactions with the S1 to S2 regions were observed ( Figure 5C ). These results explain the unique ability of talin to activate integrins and provide a structural explanation for the capacity of certain other PTB-domain-containing proteins (Huang et al., 2004) to inhibit integrin function.
Thermodynamic parameters for the binding of WT and mutant talin F3 to the b3-chimeric peptides were measured using isothermal titration calorimetry (ITC ; Table S2 and Figure S5 ). In general, mutations that disrupt the MP site, either in the b tail or talin F3, have relatively little effect on the K d values (Table S2 ). This probably arises because of a balance between enthalpy gain and entropy loss, which is consistent with stabilization of the MP helix on talin binding in the WT but not in mutant structures. In sharp contrast, the talin (W359A) mutant, which inhibits binding of the MD site of the b3 tail, reduced the affinity $1000-fold, similar to the effect of mutations in the NPxY region of the integrin tail that abrogate MD binding . These results suggest that the MD site provides a substantial fraction of the binding energy and explain why other PTB domains that only bind the MD site could readily compete with talin. Talin F3 L325R and Q381V mutants were titrated with the original b3/PIPKIg chimera, while the effect of peptide mutations (F727A and F730A) was assessed using WT talin F3. The shift maps (see Experimental Procedures) indicate that binding to the MP region (via the talin loop between S1 and S2) is markedly reduced for the Q381V and F727A mutants or completely abolished for the L325R and F730A mutants, while interactions with the MD region are retained.
An Activating Mutant in the Transmembrane Domain Is Talin Independent
We previously proposed that talin binding to the b subunit cytoplasmic domain results in a mismatch in the packing of the transmembrane regions of a and b subunits . Modeling and mutational approaches indicate that interactions between the transmembrane regions stabilize the integrin low-affinity state (Bennett, 2005; Gottschalk, 2005; Luo et al., 2005; Partridge et al., 2005) . Another interaction that helps maintain the inactive conformation is the aIIb(R995)/b3(D723) MP salt bridge (Hughes et al., 1996) . We note, however, that while breaking this link shifts the equilibrium toward the active state, it does not by itself promote full activation, which requires endogenous talin (Tadokoro et al., 2003) . To test if transmembrane mutations activate in a talin-independent manner, the apolar-to-charged mutation b3(L712R) was analyzed. A combination of this mutant with b3(Y747A), a mutation that prevents binding to the talin F3-MD site aIIbb3(L712R,Y747A), remained fully activated ( Figure 6A ), confirming that disruption of transmembrane helix packing activates integrin aIIbb3 independent of talin binding.
DISCUSSION
A combination of NMR studies, together with cell-based functional assays, has revealed how the talin F3 domain is uniquely designed to activate integrins. The talin F3 domain forms a well-defined complex with the helix-forming MP region of the b-integrin tail, and this interaction holds the key to the molecular recognition required for activation. Mutations in integrin or talin that inhibit this interaction in vitro also prevent integrin activation in cells, and mutants with intermediate functional effects in cells retain Figure 5 . b-Tail Binding to the DOK1 PTB Domain Inhibits Activation of a High-Affinity Integrin (A) CHO cells stably expressing a high-affinity chimeric integrin (abPy cells) were transiently cotransfected with empty vector (pCDNA3.1), WT talin F23, or full-length DOK1; eGFP protein was used as a transfection marker. The level of integrin activation was measured by flow cytometry of harvested cells using PAC1 antibody as described in the legend to Figure 3 . Data are an average of three or more measurements; error bars are standard deviations. (B) Overlay of the DOK1 (cyan) and talin (yellow) PTB domains. The critical differences between the two domains are the residues between strands S1 and S2. (C) Weighted shift map (see Experimental Procedures) obtained by observing 1 H-15 N-HSQC spectra on addition of the b3/PIPKIg peptide to the DOK1 PTB domain (10:1 molar ratio). Gray columns indicate residues whose peaks experienced severe line broadening in the bound state and could not be assigned.
a partial ability to form the F3-MP interaction (compare Figures 3 and 4) . These findings are consistent with previous studies that identified a variety of activating mutations within the MP region of integrins, thus establishing that this region is critical for stabilizing the low-affinity conformation Partridge et al., 2005) .
The unique feature of talin F3 that promotes interaction with the MP region of b-integrin appears to be the flexible loop between strands S1 and S2 that forms a hydrophobic pocket that accepts the side chains of F727 and F730 in the complex. The talin mutation L325R within this pocket abolishes binding to the MP region ( Figure 4 ) and thus hinders activation ( Figure 3C ). Other PTB-domain-containing proteins (DOK [''IRS-like''], Shc [''Shc-like''], and NUMB [''Dab-like'']; Uhlik et al., 2005) lack such a mobile loop and so are unlikely to interact with the MP region ( Figure 5B ). Indeed, we showed that DOK binds and inhibits integrin activation and that binding occurs to the MD site but not the MP site ( Figure 5 ). Several point mutants in talin also transform the F3 domain from an activator into an inhibitor ( Figure 3D ). This is consistent with competition between endogenous talin and various PTB domains, including mutated talin F3, for the MD site. The concept of inhibition of talin activation by competitive binding to the b tails by a variety of proteins, especially those with PTB domains, may be an important feature in the regulation of integrin activity. These conclusions also apply to PTB (F3) subdomains in other FERM-domain proteins. The FERM-domain structures of band 4.1, ezrin, radixin, and moesin all have very short loops between strands 1 and 2 with no hydrophobic residues that could bury the two integrin phenylalanines Han et al., 2000; Smith et al., 2003) .
Integrin activation is critical for a variety of pathological events such as thrombosis, inflammation, and tumor metastasis (Campbell and Ginsberg, 2004) . The interface between the MP region of b3 and talin suggests that it might be readily accessible to pharmacological inhibition. The inhibitory talin mutants provide interesting tools to study talin, as they should maintain other talin functions, including the formation of links to the cytoskeleton and other focal adhesion proteins.
How does the talin/MP interaction lead to activation? One possibility is that the configuration of the complex disrupts the putative salt bridge between aIIb(R995) and b3(D723). Several distinct models for the a-b tail complex have been published, and the F3-MP complex would Figure 6 . Effect of a Transmembrane Integrin Mutation and Talin S1-S2 Loop Lysine Mutations on Integrin Activation (A) CHO cells were transiently transfected with plasmids encoding aIIb and b3 or mutants thereof, and the cells were double-stained with PAC1 and D57 to measure integrin activation and aIIbb3 expression, respectively. Integrin activation was estimated as described in the legend to Figure 3 . Both the putative transmembrane-shortening b3(L712R) mutation and the salt-bridge-breaking aIIb(R995A) mutation result in an activated integrin. However, when paired with a mutation that disrupts talin binding to form aIIb(R995A)b3(Y747A), the R995A mutation loses the ability to induce the high-affinity state, whereas the b3(L712R) mutation's activation level is unchanged in the aIIbb3(L712R, Y747A) integrin. (B) CHO cells stably expressing aIIbb3 (A5 cells) were transiently cotransfected with vectors for WT or mutant HA-tagged talin F23 and eGFP protein as a transfection marker. PAC1 binding was assessed in the GFPexpressing subset of cells by flow cytometry and analyzed as described in the legend to Figure 3 . Mutation of lysine K320 (K320D), a residue that is predicted to point away from the membrane, had no effect on activation, while mutation of K322 (K322D), a residue that is predicted to be directed toward the membrane, prevented activation. The inset to (B) shows representative western blots of cell lysates probed with anti-HA antibody and indicate that WT and mutant HA-talin F23 expressed to similar levels. The data are an average of three of more measurements; error bars are standard errors of the mean.
sterically prevent the formation of the salt bridge in some of these (Gottschalk, 2005; Vinogradova et al., 2002; Weljie et al., 2002;  Table S3 ). We note, however, that while breaking this salt bridge seems to be necessary, it is not sufficient for full activation ( Figure 3A ; Tadokoro et al., 2003) . Prevention of b3 binding to the MD site by the b3(Y747A) mutation also inhibits activation of the aIIb(R995A)b3 ( Figure 3 ) and b3(D723R) forms of integrin (data not shown). Talin binding to the MD site might contribute to activation by displacing this part of the integrin tail from a membrane-anchored position (Vinogradova et al., 2004) ; however, it is hard to reconcile this idea with the inactive state of the aIIb(R995A)b32(F727A) or aIIb(R995A)b3(F730A) integrins ( Figure 3B ) in spite of destabilization of the salt bridge and talin still binding via the MD site. In contrast, our data suggest that the primary function of the talin/MD interaction is to provide an initial strong linkage between talin and integrin and that activation arises from the subsequent talin/MP interaction.
We have proposed that activation involves disruption of transmembrane helix interactions . A related model with the additional possibility of homoand heterodimeric interactions has been proposed by Li et al. (2005) , and interactions between membrane-spanning regions have also been modeled (Gottschalk, 2005) and implied by leucine mutagenesis (Luo et al., 2005) . Glycosylation mapping was used to explore whether the membrane-spanning regions changed positions in the membrane (Stefansson et al., 2004) . Here we made a mutation in the membrane-spanning region, b3(L712R), which is expected to reposition the transmembrane helix, thus allowing the arginine guanidinium group to snorkel out of the bilayer into a more hydrophilic environment.
The activating yet talin-independent property of b3(L712R) (Figure 6 ) is consistent with integrin activation that involves repositioning of the b-transmembrane helix. Since in the absence of other proteins integrins are in equilibrium between the inactive and active states, one possibility is that the b-integrin subunit transmembrane domain is dynamic, bobbing in and out of the membrane, with its transmembrane helices sampling various degrees of burial within the bilayer. Formation of a stable MP-b3 helix in intimate contact with talin F3 would promote a conformation in which transmembrane domain residues are further out of the membrane than in the ''off state,'' pushing the equilibrium toward the active conformation.
The structure-function analysis reported here provides a cogent structural model to explain talin-dependent integrin activation (Figure 7 ). When the F3 domain engages the b-MP region, additional favorable electrostatic contacts between F3 and the lipid head groups can be made. For example, two lysine residues (316 and 322) within the large S1-S2 loop, which contacts the N-terminal end of the b-MP helix, would point toward the acidic head groups of the membrane bilayer. K343 and K345 from the flanking loop also contribute to making the MP surface of Site-Directed Mutagenesis Site-directed mutations in both the aIIbb3 subunits and the talin F3 construct were generated using the QuikChange mutagenesis kit (Stratagene). Mutants were confirmed by DNA sequencing.
Flow Cytometry
For experiments to assess the functional effect of point mutants in the b3 tail, CHO cells were cotransfected with pCDM8 plasmids coding for WT or mutant sequences of aIIb and b3. Transfection was done using the Plus Reagent and Lipofectamine (Invitrogen Life Technologies); 24 hr later cells were stained with B-D57 and PAC1 in the presence and absence of Ro43-5054 or anti-LIBS6. The biotinylated monoclonal antibody B-D57 was used to detect expression of aIIbb3, while PAC1, an activation-specific, monoclonal IgM antibody, was used to assess the activation state of the aIIbb3 integrin. This antibody is an authentic ligand for integrin aIIbb3 (Abrams et al., 1994) , and its binding correlates with the binding of natural ligands such as fibrinogen (Shattil et al., 1985) . Cells were analyzed on a FACScan using both B-D57 and PAC1 antibodies as described previously . The geometric mean fluorescence intensity (MFI) of PAC1 staining in the presence of Ro43-5054 (2 mM) was used to estimate nonspecific PAC1 binding (F 0 ). The fluorescence intensity in the presence of anti-LIBS6 was used to estimate maximal PAC1 binding (F max ) since anti-LIBS6 directly induces aIIbb3 binding to PAC1 regardless of the status of cellular activation mechanism (Baker et al., 1997) . The activation index was calculated using the formula: 100 3 (F À F 0 ) / (F max À F 0 ), where F = MFI under the test condition.
For experiments to assess the functional effect of F3-domain mutations, WT or mutant versions of pCDNA3.1 plasmids coding for N-terminally HA-tagged proteins consisting of the F2 and F3 domains of mouse talin (residues 206-405; Swiss-Prot P26039) were transiently transfected into cells stably expressing WT aIIbb3, an aIIb(D723A)b3 mutant or an aIIba6Ab3b1A-chimeric integrin (abPy cells; Baker et al., 1997) . In these experiments eGFP vector was cotransfected as a transfection marker at a HA-F23/eGFP ratio of 20:1.
Calorimetry ITC was performed on a VP-ITC calorimeter (Microcal, Northampton, MA, USA). Aliquots (8 ml) of WT (KKLLITIHDRKEFAKFEEERARAKWVpYSPLHYSAR) or mutant chimeric peptide were injected into the cell containing WT or mutant talin F3 domain. Peptide concentrations were typically 150 to 300 mM, while protein concentrations ranged from 25 to 50 mM. For the W359A mutant, the protein concentration was 50 mM, and the peptide concentration was 1 mM. Prior to ITC titrations, the peptides and proteins were in 200 mM Tris, 300 mM NaCl, pH 7.5. In each experiment 37 injections were made. The experiments were performed at 23 C. All titrations were performed at least twice and with different protein preparations. Experimental data were analyzed using MicroCal Origin software.
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